Publications by authors named "Y Abdou"
Background: The phase III RxPONDER trial has impacted treatment for node-positive(1-3), hormone receptor-positive, HER2-negative breast cancer with 21-gene recurrence score (RS) ≤ 25. We investigated how these findings apply to different racial and ethnic groups within the trial.
Methods: The trial randomized women to endocrine therapy (ET) or to chemotherapy plus ET.
Introduction: Clinicopathologic and patient factors, such as tumor grade, size, age, and menopausal status, provide limited prognostic and predictive information in hormone receptor positive (HR +), human epidermal growth receptor 2 negative (HER2-), node-negative early-stage breast cancer, leading to potential over- or under-treatment. Multigene expression profile tests used in clinical practice in the USA, including the 21-gene assay, 70-gene assay, 12-gene assay, and 50-gene assay, offer prognostic information beyond traditional clinicopathologic features to improve treatment decisions. This study aimed to estimate the cost-effectiveness of these four multigene assays compared with clinicopathologic risk assessment alone.
View Article and Find Full Text PDFArticle Synopsis
- Sacituzumab govitecan (SG) is effective for treating metastatic triple-negative breast cancer (mTNBC), with a median overall survival of 9.6 months in heavily pretreated patients.
- A study of 115 female patients showed that over half experienced significant adverse events, leading to dose adjustments in over half of the cases.
- For patients with HER2-low mTNBC receiving trastuzumab deruxtecan (T-DXd) after SG, the objective response rate was 34.8%, indicating that sequential treatments can be beneficial.
Purpose: Understanding quality of life (QOL) implications of individual components of breast cancer treatment is important as systemic therapies continue to improve oncologic outcomes. We hypothesized that adjuvant radiation therapy does not significantly impact QOL domains in breast cancer patients undergoing chemotherapy.
Methods: Data was drawn from three prospective studies in women with localized breast cancer being treated with chemotherapy from March 2014 to December 2019.